Scientific Evidence Demonstrates OPTAVIA®'s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients
MWN-AI** Summary
Medifast® (NYSE: MED) has announced significant advancements in its OPTAVIA® metabolic health system, which is now eligible for reimbursement through select insurance plans using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). This enables clients to save up to 40% on program costs, making it more accessible for individuals focused on improving metabolic health. With over 90% of U.S. adults classified as metabolically unhealthy, Medifast aims to address this pressing health concern through its scientifically-backed program, which combines diet, coaching, and behavioral support to target the underlying causes of metabolic dysfunction.
Nicholas Johnson, President of Medifast, emphasized the importance of this development in providing innovative health solutions to millions seeking ways to enhance their well-being. The OPTAVIA program centers around Metabolic Synchronization™, a unique approach that facilitates a metabolic reset by promoting healthy weight loss, specifically aiming to reduce visceral fat while preserving lean muscle mass. This dual approach not only promotes weight loss but also improves body composition and restores metabolic balance.
Supporting these claims, clinical research shows that participants on the Optimal Weight 5 & 1 Plan® retained nearly 98% of their lean mass while experiencing a significant 14% reduction in visceral fat over a 16-week period. Looking ahead, Medifast plans to launch new products in 2026 that will incorporate clinically studied ingredients tailored for enhanced metabolic health, underscoring its commitment to providing adaptable solutions for every stage of individuals' health journeys.
With over 40 years of clinical experience, Medifast remains dedicated to its mission of transforming lives through sustainable health practices. For more information, visit www.MedifastInc.com.
MWN-AI** Analysis
Medifast's recent announcement regarding the reimbursement of OPTAVIA’s metabolic health program through select Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) presents a unique investment opportunity for industry stakeholders and investors. The move aligns with a growing trend toward preventive healthcare solutions, as more Americans are prioritizing metabolic health, with alarming statistics indicating that over 90% of U.S. adults are considered metabolically unhealthy.
By allowing clients to save substantially—up to 40%—on program costs through the utilization of pre-tax funds, Medifast enhances accessibility and encourages adoption among those seeking effective solutions for weight management and metabolic balance. The protocol’s scientific foundation, particularly the Metabolic Synchronization™ system, targets visceral fat reduction while preserving lean mass, offering not just weight loss but improved body composition and overall metabolic function.
Investors should consider the potential for market growth as the company prepares to launch a new line of products in 2026 that will incorporate clinically studied ingredients aimed at further supporting metabolic health. This innovation signals Medifast’s commitment to evolving its offerings, maintaining its competitive edge in the health and wellness sector.
Moreover, with the continuous push for science-backed health solutions and preventive care, Medifast is strategically positioned to benefit from increasing consumer demand and market trends that prioritize long-term wellness. Industry analysts should monitor Medifast's sales growth and client adoption rates as more individuals seek to leverage their HSA/FSA funds for health improvement programs. Given these factors, Medifast (MED) could present a compelling entry point for investors looking to capitalize on the intersection of health and wellness and the evolving healthcare landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
As part of its continued focus on improving metabolic health, Medifast ® (NYSE: MED) today announced that OPTA VIA ’s comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). OPTA VIA clients may be able to save up to 40% on program costs by working with their medical provider and insurance administrator to use pre-tax medical funds, offering accessibility for those prioritizing their metabolic health.
This milestone reinforces Medifast’s position as a science-driven health and wellness leader, with a metabolic reset plan that reverses metabolic dysfunction — a widespread but often overlooked health concern, with more than 90% of U.S. adults classified as metabolically unhealthy. 1 OPTA VIA is designed to address these challenges head-on, combining a science-backed system with coaching to guide clients toward improvements in their metabolic health, targeting the root cause of metabolic dysfunction.
“This is a major moment for our company, and more importantly, for the millions of people across the U.S. seeking solutions for improving their health,” said Nicholas Johnson, President of Medifast. “With OPTA VIA's metabolic health system available on select insurance plans using HSA and FSA funds, we're encouraging more people to access the innovative tools and science-backed solutions they need to help promote metabolic health.”
OPTA VIA’s approach is rooted in our breakthrough science, Metabolic Synchronization™, which resets the body’s metabolism through healthy, quality weight loss, targeting visceral fat reduction, preserving lean mass and protecting healthy muscle. 2
“With Metabolic Synchronization, we’re empowering individuals to take control of their metabolic health,” said Dr. Satya Jonnalagadda, Vice President of Scientific & Clinical Affairs at Medifast. “Our science-backed solutions achieve more than just weight loss — they improve body composition by reducing visceral fat, preserving lean mass and protecting healthy muscle, which are critical to restoring metabolic balance.”
Using the science of Metabolic Synchronization, Medifast plans to launch a new system in 2026 featuring products that incorporate clinically studied ingredients designed to further support metabolic health, marking the next step in the company’s ongoing commitment to providing solutions that adapt to every stage of the health journey.
1 O’Hearn M et al. Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018. J Am Coll Cardiol. 2022; 80(2):138-151. doi:10.1016/j.jacc.2022.04.046 |
2 In a clinical study, 98% of lean mass was retained and individuals experienced a reduction of 14% visceral adiposity [visceral fat] on the Optimal Weight 5 & 1 Plan® at 16 weeks. Arterburn LM, et al. Randomized controlled trial assessing two commercial weight loss programs in adults with overweight or obesity. Obes Sci Pract. 2018;5(1):3-14. doi: 10.1002/osp4.312. |
About Medifast
Medifast (NYSE: MED) is the health and wellness company known for its science-backed, coach-guided lifestyle system. Designed to address the challenges of metabolic dysfunction, the company's holistic approach integrates personalized plans, scientifically developed products and a framework for sustainable habit creation — all supported by a dedicated network of independent coaches.
Driven to improve metabolic health through advanced science and comprehensive behavioral support, Medifast has introduced Metabolic Synchronization™, a breakthrough science that reverses metabolic dysfunction through targeted metabolic reset. Research demonstrates that the company's comprehensive system activates strong and targeted fat burning to enhance metabolic health and body composition by reducing visceral fat, preserving lean mass and protecting muscle integrity.
Backed by more than 40 years of clinical heritage, Medifast continues to advance its mission of Lifelong Transformation, Making a Healthy Lifestyle Second Nature®. For more information, visit www.MedifastInc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260219393923/en/
Media Contact
Jessica Oring, jessica.oring@medifastinc.com
FAQ**
How is MEDIFAST INC MED leveraging the integration of HSA and FSA reimbursement options to enhance the adoption of its OPTA VIA program among clients seeking metabolic health solutions?
What clinical evidence supports the claims of MEDIFAST INC MED regarding the efficacy of the Metabolic Synchronization™ approach in improving metabolic health and body composition?
Considering the high percentage of U.S. adults classified as metabolically unhealthy, how does MEDIFAST INC MED plan to expand the reach of its OPTA VIA program to address this growing health concern?
What innovations or new products can we expect from MEDIFAST INC MED in 2026 as part of its ongoing commitment to advancing metabolic health solutions through clinical research?
**MWN-AI FAQ is based on asking OpenAI questions about MEDIFAST INC (NYSE: MED).
NASDAQ: MED
MED Trading
2.71% G/L:
$10.805 Last:
59,177 Volume:
$10.58 Open:
